BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

Deep News08-23 12:50

BofA Securities has released a research report indicating that CSPC PHARMA (01093) saw its total revenue and attributable net profit surge by 40.1% and 139.2% year-on-year, respectively, reaching RMB 18.6 billion and RMB 6.1 billion in the first half of the year.

For the second quarter alone, total revenue climbed 93.8% year-on-year to RMB 12.1 billion, while attributable net profit jumped 389.3% to RMB 5.2 billion.

The firm has raised its net profit estimates for CSPC PHARMA for the 2026 to 2028 period by 1.9%, 2.6%, and 1.6%, respectively, and lifted the target price from HK$7.6 to HK$8.6.

However, due to pricing pressures on the key drug NBP (恩必普), BofA Securities has reiterated its "Underperform" rating on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment